Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer

HER2 receptor tyrosine kinase (encoded by the ERBB2 gene) is overexpressed in approximately 25% of all breast cancer tumors (HER2-positive breast cancers). Resistance to HER2-targeting therapies is partially due to the loss of HER2 expression in tumor cells during treatment. However, little is known...

Descripción completa

Detalles Bibliográficos
Autores principales: Nami, Babak, Ghanaeian, Avrin, Black, Corbin, Wang, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472246/
https://www.ncbi.nlm.nih.gov/pubmed/34575017
http://dx.doi.org/10.3390/life11090868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472246/
https://www.ncbi.nlm.nih.gov/pubmed/34575017
http://dx.doi.org/10.3390/life11090868

Ejemplares similares